Abstract
Chagas disease (CD) is a neglected tropical disease caused by the parasitic protozoan Trypanosoma cruzi. However, only 20% to 30% of infected individuals will progress to severe symptomatic cardiac manifestations. Current treatments are benznidazole and nifurtimox, which are poorly tolerated regimens. Developing a biomarker to determine the likelihood of patient progression would be helpful for doctors to optimize patient treatment strategies. Such a biomarker would also benefit drug discovery efforts and clinical trials. In this study, we combined untargeted and targeted metabolomics to compare serum samples from T. cruzi-infected individuals who progressed to severe cardiac disease, versus infected individuals who remained at the same disease stage (non-progressors). We identified four unannotated biomarker candidates, which were validated in an independent cohort using both untargeted and targeted analysis techniques. Overall, our findings demonstrate that serum small molecules can predict CD progression, offering potential for clinical monitoring.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by NIH award number R21AI156669. Samples were from the Johns Hopkins-Universidad Peruana Cayetano Heredia Collaborated Studies Chagas disease biorepository, with prior sample collection, clinical data collection and some salary support to R.H.G and N.M.B. supported by NIH award number R01AI107028. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Serum samples were from the Johns Hopkins-Universidad Peruana Cayetano Heredia Collaborated Studies Chagas disease biorepository, Johns Hopkins Institutional Review Board (IRB) approval number IRB00007176. Initial sample collection was under Johns Hopkins Institutional Review Board (IRB) approval number IRB00009799.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The untargeted MS data generated in this study have been deposited in the MassIVE database for positive mode pHILIC: (MSV000092754), negative mode pHILIC (MSV000092756), positive mode polar C18 (MSV000092757), and negative mode polar C18 (MSV000092758). Feature-based molecular networking for untargeted MS data can be accessed at: https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=ad84b5b572864898a733f159320bbd12 (positive mode pHILIC), https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=7c725bc5bd23485dad48f5e3d6a5a84a (negative mode pHILIC), https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=73c7f72874d64fe78c9f97657df45bee (positive mode polar C18), https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=1e4c73cec97a4f09bbbd126da52a7262 (negative mode polar C18). The targeted MS data for PRM validation have been deposited in the MassIVE database for positive mode pHILIC (MSV000093740), negative mode pHILIC (MSV000093741), positive mode polar C18: (MSV000093742), and negative mode polar C18 (MSV000093743). Representative code has been deposited on GitHub, at https://github.com/zyliu-OU/McCall-Lab/tree/main/05092023.
Abbreviations used
- CD
- Chagas disease
- HILIC
- Hydrophilic interaction chromatography
- LC-MS/MS
- liquid chromatography-tandem mass spectrometry
- PRM
- parallel reaction monitoring
- RT
- retention time